What is Respiri?
Respiri Limited, formerly iSonea Limited, is an Australian-based e-health company specializing in the research, development, and commercialization of medical devices and mobile health applications. Its flagship product, Wheezo, is an advanced asthma management tool designed to empower users by providing comprehensive insights into their condition. Wheezo tracks triggers, symptoms, medication adherence, and other critical events, offering a data-driven approach to asthma care. The company operates in both Australia and Israel, aiming to enhance patient outcomes through accessible technology.
How much funding has Respiri raised?
Respiri has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed
What's next for Respiri?
With the recent injection of major strategic investment and a substantial overall funding base of $12.5M, Respiri is well-positioned for its next phase of growth. The company's focus on developing user-centric asthma management solutions aligns with the increasing demand for digital health technologies. This capital is anticipated to accelerate product innovation, expand market reach, and strengthen its competitive position in the global e-health landscape. Respiri's commitment to leveraging technology for improved respiratory care suggests a trajectory aimed at significant impact and market leadership.
See full Respiri company page
